close

Data center

Explore data on the pharmaceutical industry

I'm interested in viewing data about Please select a data topicarrow_drop_down
  • Please select a data topic
  • Please select a data topic
  • The pharma industry - R&D
  • The pharma industry in figures - Economy
  • The pharma industry in figures - Employment
  • The pharma industry in figures - Healthcare
  • Value to patients
  • Value to healthcare systems
  • Value to the economy
  • Value to society
  • Medicines cost in context
  • Innovation
  • Collaborative solutions
with a focus on Please select your data focusarrow_drop_down
  • Please select your data focus
  • Please select your data focus
  • Please select your data focus
  • Pharmaceutical R&D expenditure in Europe, USA and Japan
  • R&D process
  • R&D in Europe
  • Allocation of R&D investments
  • New chemical or biological entities
  • Estimated costs of bringing a new entity to market
  • Pharmaceutical R&D expenditure - Annual growth rate (%)
  • R&D intensity
  • Impact on the European economy
  • Geographical breakdown of sales of new medicines
  • R&D expenditure in Europe, USA and Japan
  • Parallel imports
  • Production
  • World pharmaceutical market
  • Market value
  • VAT rates
  • Generics
  • Imports and exports
  • Trade balance (by country)
  • Trade balance - high technology sectors
  • EU main pharmaceutical trading partners
  • Employment in the pharmaceutical industry (by country)
  • Employment in the pharmaceutical industry (by year)
  • Employment in pharmaceutical R&D
  • Total spending on healthcare
  • Payment for pharmaceuticals
  • Causes of death by major disease areas
  • Breakdown of health expenditure
  • New medicines
  • Cancer mortality
  • Cancer - life expectancy
  • Hep C - cure rates
  • Chronic diseases - impact
  • Vaccines - impact
  • HIV - death rates
  • Innovation
  • Personalised medicines - Leukemia survival
  • Personalised medicines - Lung cancer
  • Rare diseases
  • Medicines benefits
  • Health gains and savings
  • The added value of medicines
  • Shift towards cure and prevention
  • Medicines and total healthcare costs
  • Industry contribution to European economy
  • R&D spending by industry
  • R&D spending as a percentage of net sales
  • Value added per employee
  • Worldwide pharmaceutical R&D investment
  • UK pharmaceutical R&D investment
  • Innovative treatments – longevity and productivity of patients
  • Clinical Trials
  • Unmet medical needs
  • Cancer survivorship and employment
  • Healthcare systems – challenges
  • Ageing population
  • Chronic disease
  • Pharmaceutical expenditure
  • Pharmaceutical expenditure in Germany
  • Cancer-related healthcare costs
  • Cost-reduction of off-patent medicines
  • Generic medicines
  • Biosimilars
  • Health outcomes
  • New medicines
  • Advances in medicines
  • Rare diseases
  • R&D spending as a percentage of net sales
  • Innovation – challenges
  • Research and development process
  • Early access
  • IMI
  • Access
  • Outcomes-driven sustainable healthcare
  • Stability agreements
  • Finding solutions
View